<DOC>
	<DOCNO>NCT00755261</DOCNO>
	<brief_summary>This research do find add drug call Avastin already approve regimen use soft-tissue sarcoma , Doxorubicin , improve overall survival , slow disease progression . The study also evaluate overall safety combine drug . It known combine drug improve outcome . Avastin approve treatment metastatic carcinoma colon rectum . It approve treatment soft-tissue sarcoma add Doxorubicin .</brief_summary>
	<brief_title>Phase II Study Doxorubicin Avastin® Sarcoma .</brief_title>
	<detailed_description>The rationale trial improve efficacy prototypical anti-sarcoma chemotherapeutic regimen Doxorubicin combine Avastin® . Soft tissue sarcoma highly vascular tumor therefore ideally suited trial combine angiogenic inhibitor chemotherapy . Several study reveal correlation prognosis surrogates angiogenesis , include microvessel density , circulate VEGF basic fibroblast growth factor ( bFGF ) . The aim study evaluate safety efficacy Avastin® combination Doxorubicin treatment advance soft-tissue sarcoma .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Pathologically confirm intermediate high grade locally advance metastatic soft tissue sarcoma . 2 . The presence measurable disease 3 . Normal renal function ( spot dipstick &lt; 2** urine protein : creatinine ratio &gt; 1.0 4 . Normal Hepatic function ( total bilirubin within JOHC normal limit , transaminase ( AST ALT &lt; 3 time upper limit normal 5 . Hematologic parameter define ANC &gt; 1500/mm³ Platelets &gt; 100,000/mm³ . 6 . Performance status 01 ECOG scale 7 . Use effective mean contraception ( men woman ) subject childbearing age 8 . No prior use mesna , adriamycin , ifosfamide Avastin® . 9 . Baseline ECHO MUGA LVEF &gt; = 5060 % . 10 . Age ≥ 18 1 . Major surgery within 28 day 2 . History proteinuria &gt; 1+ 3 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored Avastin® cancer study 4 . Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) 5 . Any prior history hypertensive crisis hypertensive encephalopathy 6 . New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix E ) 7 . History myocardial infarction unstable angina within 6 month prior study enrollment 8 . History stroke transient ischemic attack within 6 month prior study enrollment 9 . Symptomatic peripheral vascular disease 10 . Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) 11 . Evidence bleed diathesis coagulopathy 12 . Current recent ( within 10 day enrollment ) use aspirin ( &gt; 325 mg/day ) chronic use NSAIDs 13 . Current , ongoing treatment fulldose warfarin equivalent ( i.e. , unfractionated and/or low molecular weight heparin ) . 14 . Known central nervous system brain metastases 15 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study 16 . Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment 17 . Pregnant ( positive pregnancy test ) lactate 18 . Proteinuria : creatinine ( UPC ) ratio ≥ 1.0 screen Urine dipstick proteinuria ≥ 2+ ( patient discover ≥2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) . 19 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 20 . Serious , nonhealing wound , ulcer , bone fracture 21 . Known hypersensitivity component Avastin® 22 . Inability comply study and/or followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>STS</keyword>
</DOC>